Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Leases: 2019-2025

Historic Current Leases for Anika Therapeutics (ANIK) over the last 5 years, with Sep 2025 value amounting to $1.7 million.

  • Anika Therapeutics' Current Leases fell 24.74% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 24.74%. This contributed to the annual value of $1.9 million for FY2024, which is 4.98% up from last year.
  • Anika Therapeutics' Current Leases amounted to $1.7 million in Q3 2025, which was down 4.96% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Current Leases peaked at $2.3 million during Q3 2024, and registered a low of $119,000 during Q1 2021.
  • Moreover, its 3-year median value for Current Leases was $2.1 million (2023), whereas its average is $2.0 million.
  • Per our database at Business Quant, Anika Therapeutics' Current Leases surged by 1,184.03% in 2022 and then declined by 24.74% in 2025.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Current Leases stood at $1.5 million in 2021, then skyrocketed by 35.85% to $2.1 million in 2022, then dropped by 11.87% to $1.8 million in 2023, then rose by 4.98% to $1.9 million in 2024, then dropped by 24.74% to $1.7 million in 2025.
  • Its Current Leases was $1.7 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.